Liquid biopsy for early cancer detection: novel approaches show promising early signals
Novel tests based on epitranscriptomics and cfCTCF-DNA nucleoproteins aim to overcome sensitivity limitations of currently available methods
Early signs of progress in osteosarcoma research
Emerging molecular and spatial approaches are providing new insights into osteosarcoma and identifying potential targets for future therapies
AI for early-phase clinical trials: from hype to proof of concept
Growing experience suggests that artificial intelligence could potentially transform how cancer research is designed and conducted
Is artificial intelligence a reliable partner for multidisciplinary tumour boards?
Real-world findings show moderate-to-high concordance between AI-generated and human experts decisions
AI in GI cancer care: From recognition to clinical value
Experts' discussions during the ESMO Gastrointestinal Cancers Congress 2026 explored how AI is moving beyond image recognition to support surgery, pathology and image-guided intervention.
Rethinking cancer vaccines through the tumour immunopeptidome
Direct identification of specific tumour-derived HLA-bound peptide targets is enabling the development of personalised immunotherapy strategies
Reshaping the treatment landscape for GI cancers
ADCs are transforming the management of patients with GI cancers, but novel targets and combination strategies will be required to address resistance development and optimise patient outcomes
Could more complex molecular analysis aid biomarker-driven clinical management of poor-prognosis colorectal cancer?
New study findings provide support for the use of ctDNA to predict survival benefits and personalise treatments
Treatment duration of immunotherapy combination does not impact on disease-free survival in dMMR colon cancer
An ATOMIC study pre-planned exploratory analysis reports no DFS benefit with the addition of immunotherapy in patients receiving fewer than six cycles of chemotherapy
Adagrasib plus cetuximab fails to outperform chemotherapy in KRAS G12C-mutated metastatic colorectal cancer
The phase III KRYSTAL-10 trial did not meet its co-primary survival endpoints